Tigirate 200

Generic

 

Indications

Fenofibrate is demonstrated for hyperlipidemias of sort lla, llb, III, IV & V in patients who have not reacted satisfactorily to count calories & other fitting measures.

 

Pharmacology

Fenofibrate may be a fibric corrosive subsidiary. Fenofibrate is quickly hydrolyzed after verbal ingestion to its pharmacologically dynamic frame, fenofibric corrosive. Fenofibric corrosive produces diminishments in add up to cholesterol, LDL cholesterol, Apo-lipoprotein B, Add up to triglycerides and VLDL. In expansion, treatment with Fenofibrate comes about in increments in HDL and apo-proteins apoAI apoAII. Fenofibrate too diminishes serum uric corrosive levels in hyperuricemic and ordinary people by expanding the urinary excretion of uric corrosive. The micronised shape of Nofiate (Fenofibrate) has improved retention over the non-micronised detailing.

 

Administration & Dosage

• For the treatment of adult patients with hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenofibrate is 200 mg per day.
• For adult patients with hypertriglyceridemia, the initial dose is 67 to 200 mg per day.
• Dose should be individualized according to patient response. Fenofibrate should be given with meal there by, optimizing the bioavailability of the medication. Or, as directed by the registered physician.

 

Interaction

Fenofibrate is contraindicated in patients with touchiness to Fenofibrate, serious renal or hepatic disability, existing rankle bladder illness, breast bolstering moms, photosensitivity to ketoprofen.

 

Contraindications

Fenofibrate is contraindicated in patients with hypersensitivity to Fenofibrate, severe renal or hepatic impairment, existing gall bladder disease, breast feeding mothers, photosensitivity to ketoprofen.

 

Side Effect

Gastro-intestinal (e.g. nausea, anorexia, gastric pain), pruritus, urticaria, impotence, also headache, dizziness, vertigo, fatigue, hair loss; myotoxicity.

 

Pregnancy & Lactation

Fenofibrate is not recommended for pregnant women.

 

Precautions & Warnings

Extraordinary care required in patients with renal infection, as dynamic increments in serum creatinine concentration or disappointment to take after dose rules may result in myotoxicity; cease in case myotoxicity suspected or creatinine kinase concentration increments altogether. Liver work tests suggested each 3 months for to begin with year.

 

Therapeutic Class

Fibrates

 

Storage Conditions

Protect from light and moisture by storing below 30°C. Keep the medicine out of children's reach.

 

Pharmaceutical Name